Search

Your search keyword '"Biological products industry -- Licensing agreements"' showing total 2,216 results
Start Over Descriptor "Biological products industry -- Licensing agreements"
2,216 results on '"Biological products industry -- Licensing agreements"'

1. ArriVent BioPharma inks exclusive license with Lepu Biopharma for MRG007, an ADC to treat gastrointestinal cancers

Subjects
Licensing agreements, Company licensing agreement, Cancer, Biological products -- Licensing agreements, Biological products industry -- Licensing agreements
Abstract

ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, announced that it has entered into an exclusive license agreement with Lepu Biopharma Co., [...]

Published
2025

2. Valneva signs exclusive license agreement with Serum Institute of India for its single-shot chikungunya vaccine to supply in Asia

Subjects
Valneva SE -- Licensing agreements, Serum Institute of India Private Ltd. -- Licensing agreements, Coalition for Epidemic Preparedness Innovations, Licensing agreements, Company licensing agreement, Vaccines -- Licensing agreements, Epidemics -- Asia -- India, Contraceptives industry -- Licensing agreements, Biological products industry -- Licensing agreements
Published
2024

4. Dr. Reddy's signs licensing agreement with Gilead for lenacapavir in India

Subjects
Dr. Reddy's Laboratories Ltd. -- Licensing agreements, Biological products industry -- Licensing agreements, Drug approval, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Dr. Reddy's Laboratories has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the manufacture and commercialisation of the drug, Lenacapavir, in India and 120 [...]

Published
2024

5. Hetero signs licensing agreement with Gilead expanding access to Lenacapavir

Subjects
Biological products industry -- Licensing agreements, Sexually transmitted diseases -- Prevention, AIDS treatment, Company licensing agreement, Business, News, opinion and commentary
Abstract

Hetero announced a new partnership with Gilead Sciences Ireland UC for a non-exclusive, royalty-free voluntary licensing agreement to manufacture and distribute lenacapavir in 120 primarily low- and lower- middle income [...]

Published
2024

6. Gilead in royalty-free generic manufacturing deals for lenacapavir for HIV

Subjects
Gilead Sciences Inc. -- Licensing agreements, Dr. Reddy's Laboratories Ltd. -- Licensing agreements, Biological products industry -- Licensing agreements, HIV (Viruses), Generic drugs -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Gilead Sciences announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, [...]

Published
2024

7. Full-Life Technologies, SK Biopharma ink licensing agreement for novel therapeutic targeting multiple solid tumours

Subjects
Licensing agreements, Health aspects, Company licensing agreement, Tumors -- Health aspects, Biological products -- Licensing agreements, Biological products industry -- Licensing agreements, Scientific equipment industry -- Licensing agreements, Scientific equipment and supplies industry -- Licensing agreements
Abstract

Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, announced that it has entered into a license agreement with SK Biopharmaceuticals, a global biotech company, for exclusive worldwide clinical research, [...]

Published
2024

8. Sangamo Enters License Pact with Genentech

Subjects
Roche Holding AG -- Licensing agreements, Biological products industry -- Licensing agreements, Nervous system diseases, Biotechnology industry -- Licensing agreements, Alzheimer's disease, Company licensing agreement, Arts and entertainment industries
Abstract

Sangamo Therapeutics, a genomic medicine company, reported it has entered into a license agreement with Genentech, a member of the Roche Group, to develop intravenously administered genomic medicines to treat [...]

Published
2024

9. Sangamo enters license agreement with Genentech

Subjects
Licensing agreements, Company licensing agreement, Nervous system diseases, Biological products industry -- Licensing agreements, Alzheimer's disease
Abstract

Sangamo (SGMO) announced it has entered into a license agreement with Genentech, a member of Roche (RHHBY), to develop intravenously administered genomic medicines to treat certain neurodegenerative diseases. Sangamo has [...]

Published
2024

10. Full-Life Technologies inks license agreement with SK Biopharma for novel therapeutic targeting multiple solid tumors

Subjects
Licensing agreements, Health aspects, Company licensing agreement, Tumors -- Health aspects, Biological products -- Licensing agreements, Biological products industry -- Licensing agreements, Scientific equipment industry -- Licensing agreements, Scientific equipment and supplies industry -- Licensing agreements
Abstract

Full-Life Technologies, a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China, announced that it has entered into a license agreement worth $571.5 million with SK Biopharmaceuticals, [...]

Published
2024

11. Relay Therapeutics announces termination of license agreement with Genentech

Subjects
Genentech Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

In a regulatory filing, Relay Therapeutics (RLAY) announced that on July 11, the company received notice of termination of the Collaboration and License Agreement, dated December 11, 2020, as amended [...]

Published
2024

12. RedHill Biopharma terminates license agreement for Aemcolo

Subjects
Biological products industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary, Aemcolo (Medication) -- Licensing agreements
Abstract

RedHill Biopharma announced the mutual decision with Cosmo Technologies to voluntary terminate their exclusive U.S. license agreement for Aemcolo, a treatment for traveler's diarrhea. The License Agreement, initially dated October [...]

Published
2024

13. Accord BioPharma Strengthens Pipeline Through Exclusive U.S. Licensing Agreement with Bio-Thera for BAT2506, a Proposed Golimumab Biosimilar

Subjects
Simponi (Medication) -- Licensing agreements, Licensing agreements, Company licensing agreement, Tumor necrosis factor, Rheumatoid factor, Monoclonal antibodies, Golimumab, Biological products industry -- Licensing agreements
Abstract

RALEIGH: Accord BioPharma has issued the following news release: Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, Ltd. ('Intas Pharmaceuticals'), focused on the development of oncology, immunology and [...]

Published
2025

14. ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers

Subjects
Licensing agreements, Company licensing agreement, Cancer, Biopharmaceuticals -- Licensing agreements, Antibodies, Biological products industry -- Licensing agreements, Biopharmaceutics -- Licensing agreements, Viral antibodies
Abstract

NEWTOWN SQUARE: ArriVent BioPharma, Inc. has issued the following news release: ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of innovative [...]

Published
2025

15. Biopharma Artificial Intelligence (AI) Collaboration and Licensing Deals Trends Analysis Report 2024: Access to 887 Agreements Signed Since 2019 - Upfront, Milestone, Royalties, Company, and Therapy

Subjects
Biological products industry -- Licensing agreements, Artificial intelligence -- Reports, Royalties -- Reports, Artificial intelligence, Company licensing agreement, General interest, News, opinion and commentary
Abstract

DUBLIN: RESEARCH AND MARKETS has issued the following news release: The 'Artificial Intelligence (AI) Collaboration and Licensing Deals 2019-2024' report has been added to ResearchAndMarkets.com's offering. This report contains a [...]

Published
2024

17. Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target

Subjects
Gilead Sciences Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Tumors, Biological products -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

- Single-Asset Focused Collaboration, License, and Option Agreement Combines Tubulis' Differentiated ADC Platform Technologies with Gilead's Oncology Research and Development Expertise - - Agreement Provides Gilead with Exclusive Option to [...]

Published
2024

18. Xeris Biopharma enters collaboration, license agreement with Beta Bionics

Subjects
Biological products industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Xeris Biopharma has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris' XeriSol technology for [...]

Published
2024

19. Xeris Biopharma enters exclusive license agreement with Beta Bionics

Subjects
Biological products industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Xeris Biopharma announced that it has entered into an exclusive worldwide collaboration and license agreement with Beta Bionics, Inc. for the development and commercialization of a glucagon product utilizing Xeris' [...]

Published
2024

20. ABVC BioPharma inks licensing agreement with OncoX; expecting aggregate income of $13.75 mn and royalties of up to $12.50 mn

Subjects
Licensing agreements, Company licensing agreement, Non-small cell lung cancer, Biological products industry -- Licensing agreements, Lung cancer, Non-small cell
Abstract

ABVC BioPharma, Inc, a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, has announced that the company, together with its affiliate Rgene Corporation entered [...]

Published
2024

21. MaxCyte signs strategic platform license with Be BioPharma

Subjects
Biological products industry -- Licensing agreements, B cells, Company licensing agreement, Business, News, opinion and commentary
Abstract

MaxCyte and Be BioPharma announced the signing of a strategic platform license, SPL, to support the development of Be Bio's BCMs programs. Under the terms of the agreement, Be Bio [...]

Published
2024

22. Gilead, Xilio ink exclusive license agreement to develop and commercialize tumour-activated IL-12 programme, XTX301

Subjects
Gilead Sciences Inc. -- Licensing agreements, Licensing agreements, Company licensing agreement, Tumors, Biological products industry -- Licensing agreements
Abstract

Gilead Sciences, Inc. and Xilio Therapeutics, Inc. announced an exclusive license agreement to develop and commercialize Xilio's phase 1 tumour-activated IL-12 programme, XTX301. Xilio Therapeutics is a clinical-stage biotechnology company [...]

Published
2024

23. Xilio Therapeutics, Gilead announce exclusive license agreement for XTX301

Subjects
Gilead Sciences Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Cash transactions, Company licensing agreement, Business, News, opinion and commentary
Abstract

Gilead Sciences (GILD) and Xilio Therapeutics (XLO) announced an exclusive license agreement to develop and commercialize Xilio's Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a clinical-stage biotechnology company [...]

Published
2024

24. ProBioGen, Mapp Biopharmaceutical partner to develop afucosylated antibody against Marburg virus disease using GlymaxX technology

Subjects
Mapp Biopharmaceutical, Inc. -- Licensing agreements, Licensing agreements, Health aspects, Company licensing agreement, Marburg virus disease -- Health aspects, Infection -- Health aspects, Virus diseases -- Health aspects, Antibodies -- Health aspects, Biological products industry -- Licensing agreements, Viral antibodies -- Health aspects
Abstract

ProBioGen, a leading CDMO of innovative solutions and services for biopharmaceutical development, announced the execution of services and license agreements with Mapp Biopharmaceutical, Inc. to develop a cell line for [...]

Published
2024

25. Accord BioPharma signs commercialisation and licence agreement with Bio-Thera Solutions

Subjects
Licensing agreements, Company licensing agreement, Monoclonal antibodies, Golimumab, Biological products industry -- Licensing agreements
Abstract

M2 EQUITYBITES-February 11, 2025-Accord BioPharma signs commercialisation and licence agreement with Bio-Thera Solutions (C)2025 M2 COMMUNICATIONS http://www.m2.co.uk Accord BioPharma Inc, the US specialty division of India-based Intas Pharmaceuticals Ltd, announced [...]

Published
2025

26. Accord BioPharma signs commercialisation and licence agreement with Bio-Thera Solutions

Subjects
Licensing agreements, Company licensing agreement, Monoclonal antibodies, Golimumab, Biological products industry -- Licensing agreements
Abstract

M2 PHARMA-February 11, 2025-Accord BioPharma signs commercialisation and licence agreement with Bio-Thera Solutions (C)2025 M2 COMMUNICATIONS Accord BioPharma Inc, the US specialty division of India-based Intas Pharmaceuticals Ltd, announced on [...]

Published
2025

27. Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries

Subjects
Prevention, Licensing agreements, Company licensing agreement, AIDS treatment, HIV -- Prevention, Drug resistance -- Prevention, Biological products industry -- Licensing agreements, HIV (Viruses) -- Prevention
Abstract

HYDERABAD, India: Hetero has issued the following news release: Hetero, India's leading pharmaceutical company with the widest global reach, today announced a new partnership with Gilead Sciences Ireland UC (Gilead [...]

Published
2024

28. Dr. Reddy's inches up on signing voluntary licensing agreement with Gilead Sciences

Subjects
Dr. Reddy's Laboratories Ltd. -- Licensing agreements, Biological products industry -- Licensing agreements, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

The agreement is for the manufacture and commercialisation of the drug, Lenacapavir, in India and 120 other countries Dr. Reddy's Laboratories is currently trading at Rs. 6766.80, up by 19.85 [...]

Published
2024

29. Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences

Subjects
United States. Food and Drug Administration, Dr. Reddy's Laboratories Ltd. -- Licensing agreements, Biological products industry -- Licensing agreements, Drug approval, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

The agreement is for the manufacture and commercialisation of the drug, Lenacapavir, in India and 120 other countries Dr. Reddy's Laboratories has entered into a royalty-free non-exclusive voluntary licensing agreement [...]

Published
2024

30. Emcure Pharmaceuticals signs agreement with Gilead Sciences Ireland UC

Subjects
Biological products industry -- Licensing agreements, Generic drugs -- Licensing agreements, Company licensing agreement, Business, international
Abstract

This strategic partnership underscores Emcure's commitment to innovative affordable global healthcare Emcure Pharmaceuticals has signed a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, part of California, US based [...]

Published
2024

31. Hetero Signs Voluntary Licensing Agreement with Gilead to Transform Global HIV response, Expanding Access to Groundbreaking Lenacapavir to 120 high-incidence countries

Subjects
HIV (Viruses) -- Prevention, Biological products industry -- Licensing agreements, Drug resistance -- Prevention, Sexually transmitted diseases -- Prevention, AIDS treatment, Company licensing agreement, Business, News, opinion and commentary
Abstract

- Non-exclusive voluntary license agreement enables the manufacture and distribution of lenacapavir for HIV prevention and treatment of heavily treatment-experienced patients with multi drug-resistant HIV HYDERABAD, India, Oct. 2, 2024 [...]

Published
2024

32. HIV BREAKTHROUGH DRUG LICENSING DEAL MARKS SIGNIFICANT BUT FLAWED STEP FOR ACCESS

Subjects
Gilead Sciences Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, HIV (Viruses), Generic drugs -- Licensing agreements, AIDS treatment, Company licensing agreement, News, opinion and commentary
Abstract

WASHINGTON, DC -- The following information was released by Public Citizen: Today, Gilead Sciences announced a licensing deal authorizing six generics manufacturers to sell the breakthrough HIV treatment lenacapavir in [...]

Published
2024

33. Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries

Subjects
Dr. Reddy's Laboratories Ltd. -- Licensing agreements, Biological products industry -- Licensing agreements, Drug approval -- Health aspects, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, Business, international
Abstract

HYDERABAD, India -- Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as 'Dr. Reddy's'), today announced that it has [...]

Published
2024

34. Osivax and KM Biologics Enter Exclusive License Option Agreement for Broad-Spectrum 'Universal' Influenza Vaccine in Japan

Subjects
Biological products industry -- Licensing agreements, Influenza vaccines -- Licensing agreements, Influenza, Company licensing agreement, Business, Business, international
Abstract

* KM Biologics, a Meiji Group company, has received an exclusive option to exercise an exclusive license for the development, manufacturing and commercialization of Osivax's broad-spectrum 'universal' influenza vaccine candidates [...]

Published
2024

35. GenEdit Updates on Multiyear Collaboration, License Agreement with Genentech

Subjects
Roche Holding AG -- Licensing agreements, Biological products industry -- Licensing agreements, Nucleic acids, Biotechnology industry -- Licensing agreements, Company licensing agreement, Arts and entertainment industries
Abstract

GenEdit, a developer of genetic medicines that leverage its NanoGalaxy platform for tissue-selective delivery, reported a multiyear collaboration and license agreement with Genentech, a member of the Roche Group. The [...]

Published
2024

36. BioInvent regains rights to immuno-oncology targets from Exelixis

Subjects
Exelixis Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Pharmaceuticals and cosmetics industries
Abstract

BioInvent International AB (BioInvent), a biotech company focused on the discovery and development of first-in-class immune-modulatory antibodies for cancer immunotherapy, announced that its early discovery partner Exelixis, Inc. has provided [...]

Published
2024

37. AbbVie, Umoja Biopharma enter collaboration to develop novel in-situ CAR-T cell therapies

Subjects
Licensing agreements, Company licensing agreement, Biological products industry -- Licensing agreements, T cells
Abstract

AbbVie, and Umoja Biopharma (Umoja), an early clinical-stage biotechnology company, announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja's [...]

Published
2024

38. Gilead Sciences, Compugen ink licence deal for novel pre-clinical immunotherapy programme

Subjects
Gilead Sciences Inc. -- Licensing agreements, Compugen Ltd. -- Licensing agreements, Licensing agreements, Company licensing agreement, Cancer treatment, Protein binding, Biotechnology industries -- Licensing agreements, Biological products -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Cancer -- Care and treatment
Abstract

Gilead Sciences, Inc. an American biopharmaceutical company headquartered in Foster City, California, has announced an exclusive licence deal with Compugen Ltd, a clinical-stage cancer immunotherapy company and a pioneer in [...]

Published
2023

39. Gilead expands global access to lenacapavir for HIV prevention

Subjects
Gilead Sciences Inc. -- Licensing agreements, Dr. Reddy's Laboratories Ltd. -- Licensing agreements, Biological products industry -- Licensing agreements, HIV (Viruses) -- Prevention, Sexually transmitted diseases -- Prevention, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Chemistry
Abstract

M2 PHARMA-October 2, 2024-Gilead expands global access to lenacapavir for HIV prevention (C)2024 M2 COMMUNICATIONS HIV medication company Gilead Sciences Inc (Nasdaq: GILD) announced on Wednesday that it has signed [...]

Published
2024

40. Gilead expands global access to lenacapavir for HIV prevention

Subjects
Gilead Sciences Inc. -- Licensing agreements, Dr. Reddy's Laboratories Ltd. -- Licensing agreements, Biological products industry -- Licensing agreements, HIV (Viruses) -- Prevention, Sexually transmitted diseases -- Prevention, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business
Abstract

M2 EQUITYBITES-October 2, 2024-Gilead expands global access to lenacapavir for HIV prevention (C)2024 M2 COMMUNICATIONS http://www.m2.co.uk HIV medication company Gilead Sciences Inc (Nasdaq: GILD) announced on Wednesday that it has [...]

Published
2024

41. Xbrane provides update on the ongoing out-licensing of Xdivanetm (nivolumab biosimilar candidate) and XB003 (Cimzia(r) biosimilar candidate) and its financial position

Subjects
United States. Food and Drug Administration, Biogen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Drug approval, Company licensing agreement, Business, international
Abstract

Stockholm: Xbrane Biopharma AB has issued the following news release: As communicated on 1 August 2024 and given the previously communicated delay in FDA approval of Ximluci(r) and the unforeseen [...]

Published
2024

42. Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

Subjects
Sangamo Therapeutics Inc. -- Licensing agreements, Roche Holding AG -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Drugs -- Licensing agreements, Nervous system -- Degeneration, Epigenetic inheritance, Company licensing agreement, Business, Business, international
Abstract

* Agreement leverages Sangamo's proprietary capsid delivery platform and epigenetic regulation capabilities to address certain neurodegenerative diseases * Sangamo expected to receive $50 million in near-term upfront license fees and [...]

Published
2024

43. Xbrane to regain full rights to BIIB801, a proposed biosimilar referencing CIMZIA(r)

Subjects
Biogen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Company licensing agreement, Business, international
Abstract

Stockholm: Xbrane Biopharma AB has issued the following news release: Xbrane Biopharma (publ) ('Xbrane' or the 'Company') today announced they will regain full rights to BIIB801 following a decision by [...]

Published
2024

44. RedHill Biopharma Terminates License Agreement for Aemcolo(r)

Subjects
Biological products industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary, Aemcolo (Medication) -- Licensing agreements
Abstract

TEL-AVIV: RedHill Biopharma Ltd. has issued the following news release: RedHill Biopharma Ltd. (Nasdaq: RDHL) ('RedHill' or the 'Company'), a specialty biopharmaceutical company, announced the mutual decision with Cosmo Technologies [...]

Published
2024

45. Biogen's TOFIDENCE (Tocilizumab) Approved In The EU

Subjects
Biological products industry -- Licensing agreements, Rheumatoid factor, Drug approval, Company licensing agreement, Business, international, Tofidence (Medication) -- Licensing agreements
Abstract

This week, Biogen announced that the European Commission has approved TOFIDENCE, a tocilizumab biosimilar referencing Roche's ROACTEMRA. TOFIDENCE was approved by the FDA in September 2023. TOFIDENCE is an intravenous [...]

Published
2024

46. Access to 1328 Antibody Collaboration and Licensing Deals 2019-2024: Upfront, Milestone, Royalties Data - Company A-Z, Deal Type and Therapy Area - ResearchAndMarkets.com

Subjects
Biological products industry -- Licensing agreements, Biopharmaceutics -- Licensing agreements, Viral antibodies -- Reports, Royalties -- Reports, Antibodies -- Reports, Company licensing agreement, Business, Business, international
Abstract

DUBLIN -- The 'Antibody Collaboration and Licensing Deals 2019-2024' report has been added to ResearchAndMarkets.com's offering. Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the [...]

Published
2024

47. Access to 1328 Antibody Collaboration and Licensing Deals 2019-2024: Upfront, Milestone, Royalties Data - Company A-Z, Deal Type and Therapy Area

Subjects
Biological products industry -- Licensing agreements, Biopharmaceutics -- Licensing agreements, Viral antibodies -- Reports, Royalties -- Reports, Antibodies -- Reports, Company licensing agreement, Business, Business, international
Abstract

M2 PRESSWIRE-June 27, 2024-: Access to 1328 Antibody Collaboration and Licensing Deals 2019-2024: Upfront, Milestone, Royalties Data - Company A-Z, Deal Type and Therapy Area (C)1994-2024 M2 COMMUNICATIONS RDATE:27062024 The [...]

Published
2024

49. SK bioscience, Hilleman Labs enter joint development of second-generation Zaire Ebola virus vaccine

Subjects
Prevention, Licensing agreements, Research and development, Productivity, Company licensing agreement, Vaccines -- Licensing agreements, Ebola virus, Industrial productivity, Medical research, Industrial research -- Congo (Kinshasa), Biological products industry -- Licensing agreements, Medicine, Experimental
Abstract

SK bioscience, an innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company has entered into a development licensing agreement with Hilleman [...]

Published
2023

50. Twist Bioscience enters antibody discovery, license agreement with Bayer

Subjects
Bayer AG -- Licensing agreements, Target marketing, Biological products industry -- Licensing agreements, Viral antibodies, Antibodies, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Twist Bioscience (TWST) announced an antibody discovery, option and license agreement with Bayer (BAYRY). Under the terms of the agreement, Twist Biopharma Solutions, a division of Twist Bioscience, will leverage [...]

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results